14. Any of the following within 6 months before the first dose of study treatment: • abdominal fistula • gastrointestinal perforation •bowel obstruction or gastric outlet obstruction •intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment. . •Other disorders associated with a high risk of fistula formation including PEG tube placement within 90 days before the first dose of study therapy